t allThe following is a short initial list of journal articles that we believe are relevant for parents and patients seeking information about Hyper IgM. You will find them listed out by the study name, authors, date of publication, and abstract, as well as a short summary of what we thought was relevant. We hope to keep this page updated as new relevant studies come out. They are listed them in order of most recently published.
M. Teresa de la Morena, et al.
Background: X-linked hyper-IgM syndrome (XHIGM) is a primary immunodeficiency with high morbidity and mortality compared with those seen in healthy subjects. Hematopoietic cell transplantation (HCT) has been considered a curative therapy, but the procedure has inherent complications and might not be available for all patients.
Objectives: We sought to collect data on the clinical presentation, treatment, and follow-up of a large sample of patients with XHIGM to (1) compare long-term overall survival and general well-being of patients treated with or without HCT along with clinical factors associated with mortality and (2) summarize clinical practice and risk factors in the subgroup of patients treated with HCT.
Methods: Physicians caring for patients with primary immunodeficiency diseases were identified through the Jeffrey Modell Foundation, United States Immunodeficiency Network, Latin American Society for Immunodeficiency, and Primary Immune Deficiency Treatment Consortium. Data were collected with a Research Electronic Data Capture Web application. Survival from time of diagnosis or transplantation was estimated by using the Kaplan-Meier method compared with log-rank tests and modeled by using proportional hazards regression.
Results: Twenty-eight clinical sites provided data on 189 patients given a diagnosis of XHIGM between 1964 and 2013; 176 had valid follow-up and vital status information. Sixty-seven (38%) patients received HCT. The average follow-up time was 8.5 ± 7.2 years (range, 0.1-36.2 years). No difference in overall survival was observed between patients treated with or without HCT (P = .671). However, risk associated with HCT decreased for diagnosis years 1987-1995; the hazard ratio was significantly less than 1 for diagnosis years 1995-1999. Liver disease was a significant predictor of overall survival (hazard ratio, 4.9; 95% confidence limits, 2.2-10.8; P < .001). Among survivors, those treated with HCT had higher median Karnofsky/Lansky scores than those treated without HCT (P < .001). Among patients receiving HCT, 27 (40%) had graft-versus-host disease, and most deaths occurred within 1 year of transplantation.
Conclusion: No difference in survival was observed between patients treated with or without HCT across all diagnosis years (1964-2013). However, survivors treated with HCT experienced somewhat greater well-being, and hazards associated with HCT decreased, reaching levels of significantly less risk in the late 1990s. Among patients treated with HCT, treatment at an early age is associated with improved survival. Optimism remains guarded as additional evidence accumulates.
Emily A. Leven1, Patrick Maffucci, Hans D. Ochs, Paul R. Scholl, Rebecca H. Buckley, Ramsay L. Fuleihan, & Raif S. Geha, & Coleen K. Cunningham, Francisco A. Bonilla, Mary Ellen Conley, Ronald M. Ferdman, Vivian Hernandez-Trujillo, Jennifer M. Puck, Kathleen Sullivan, Elizabeth A. Secord, Manish Ramesh, Charlotte Cunningham-Rundles
Purpose: The United States Immunodeficiency Network (USIDNET) patient registry was used to characterize the presentation, genetics, phenotypes, and treatment of patients with Hyper IgM Syndrome (HIGM).
Methods: The USIDNET Registry was queried for HIGM patient data collected from October 1992 to July 2015. Data fields included demographics, criteria for diagnosis, pedigree analysis, mutations, clinical features, treatment and transplant records, laboratory findings, and mortality.
Results: Fifty-two physicians entered data from 145 patients of ages 2 months to 62 years (median 12 years); 131 were males. Using patients’ age at last entry, data from 2072 patient years are included. Mutations were recorded for 85 subjects; 82 were in CD40LG. Eighteen subjects had non-X-linked HIGM. 40 % had a normal serum IgM and 15 %, normal IgA. Infections were reported for 91 %, with pulmonary, ear, and sinus infections being the most common. 42 % had Pneumocystis jirovecii pneumonia; 6 % had Cryptosporidium. 41 % had neutropenia. 78 % experienced non-infectious complications: chronic diarrhea (n = 22), aphthous ulcers (n = 28), and neoplasms (n = 8) including colon cancer, adrenal adenoma, liver adenocarcinoma, pancreatic carcinoid, acute myeloid leukemia, hepatoma, and, in a female with an autosomal dominant gain of function mutation in PIK3CD, an ovarian dysgerminoma. Thirteen patients had a hematopoietic marrow or stem cell transplant; three had solid organ transplants. Thirteen were known to have died (median age = 14 years).
Conclusions: Analysis of the USIDNET Registry provides data on the common clinical features of this rare syndrome, and in contrast with previously published data, demonstrates longer survival times and reduced gastrointestinal manifestations.
This it the first of three larger cohort papers that we expect to come out in 2016. This is the largest cohort we have seen so far for the US population, and although the is data comprehensive, the researchers mention that it is not always complete. The paper gives good insight into the outcomes of HIGM patients in the US. Sadly, the foundation has tracked a higher rate of mortality among HIGM patients than recorded in the USIDNET registry and this emphasizes the importance of obtaining updated data on the patients and enrolling more of the HIGM patient population. As discussed in the paper, patients can now self-enroll in the USIDNET by signing up for IDF’s PIConnect here: http://goo.gl/viQag7 by also signing up for the IDF’s ePHR system.
Kanako Mitsui-Sekinaka, MD,a Kohsuke Imai, MD, PhD,a,b Hiroki Sato, MS,c Daisuke Tomizawa, MD, PhD,b Michiko Kajiwara, MD, PhD,d Masayuki Nagasawa, MD, PhD,b Tomohiro Morio, MD, PhD,b and Shigeaki Nonoyama, MD, PhD. Saitama and Tokyo, Japan
Background: The long-term outcome of X-linked hyper-IgM syndrome (XHIM) caused by mutations in CD40LG is poor, and the only curative treatment is hematopoietic stem cell transplantation (HSCT). Objective: We sought to determine the clinical features and factors affecting outcomes in patients with XHIM. Methods We enrolled and retrospectively analyzed data from 56 Japanese patients with XHIM, including 29 patients who received HSCT. Results: The long-term survival rate was poor in those not undergoing HSCT (overall survival rate at 40 years of age, 28.2%). The overall survival rate of patients undergoing HSCT (n = 29) was significantly higher than that of those not undergoing HSCT (n = 27, P = .0231). Moreover, event-free and disease-free survival rates were significantly greater in patients 5 years old or younger at the time of transplantation (n = 14) than in older patients (n = 15). Conclusion: On the basis of these results, we concluded that HSCT improved the outcomes of patients with XHIM and that an age of 5 years or younger was optimal for the timing of HSCT because persistent infections and severe organ damage were frequently observed in patients older than 6 years.
This is one of the more recent studies (March 2015) to come out that had a large sample size (as well as data from patients not included in most of the EU and US studies). A total of 54 patients were included in the study, 29 patients had received HSCT. The study showed similar results as many of the previous studies: (i) survival rate at 40 yrs is lower than 30%, (ii) HSCT was advised, and (iii) best results for HSCT are when the patients were 5 years or younger because of persistent infections and severe organ damage were frequently observed in patients older than 6 years.
Cabral-Marques O1, Klaver S, Schimke LF, Ascendino ÉH, Khan TA, Pereira PV, Falcai A, Vargas-Hernández A, Santos-Argumedo L, Bezrodnik L, Moreira I, Seminario G, Di Giovanni D, Raccio AG, Porras O, Weber CW, Ferreira JF, Tavares FS, de Carvalho E, Valente CF, Kuntze G, Galicchio M, King A, Rosário-Filho NA, Grota MB, dos Santos Vilela MM, Di Gesu RS, Lima S, de Souza Moura L, Talesnik E, Mansour E, Roxo-Junior P, Aldave JC, Goudouris E, Pinto-Mariz F, Berrón-Ruiz L, Staines-Boone T, Calderón WO, del Carmen Zarate-Hernández M, Grumach AS, Sorensen R, Durandy A, Torgerson TR, Carvalho BT, Espinosa-Rosales F, Ochs HD, Condino-Neto A.
Hyper-IgM (HIGM) syndrome is a heterogeneous group of disorders characterized by normal or elevated serum IgM levels associated with absent or decreased IgG, IgA and IgE. Here we summarize data from the HIGM syndrome Registry of the Latin American Society for Immunodeficiencies (LASID). Of the 58 patients from 51 families reported to the registry with the clinical phenotype of HIGM syndrome, molecular defects were identified in 37 patients thus far. We retrospectively analyzed the clinical, immunological and molecular data from these 37 patients. CD40 ligand (CD40L) deficiency was found in 35 patients from 25 families and activation-induced cytidine deaminase (AID) deficiency in 2 unrelated patients. Five previously unreported mutations were identified in the CD40L gene (CD40LG). Respiratory tract infections, mainly pneumonia, were the most frequent clinical manifestation. Previously undescribed fungal and opportunistic infections were observed in CD40L-deficient patients but not in the two patients with AID deficiency. These include the first cases of pneumonia caused by Mycoplasma pneumoniae, Serratia marcescens or Aspergillus sp. and diarrhea caused by Microsporidium sp. or Isospora belli. Except for four CD40L-deficient patients who died from complications of presumptive central nervous system infections or sepsis, all patients reported in this study are alive. Four CD40L-deficient patients underwent successful bone marrow transplantation. This report characterizes the clinical and genetic spectrum of HIGM syndrome in Latin America and expands the understanding of the genotype and phenotype of this syndrome in tropical areas.
This is an important study as it is the first Hyper IgM study to come out the Registry of the Latin American Society for Immunodeficiencies. With a total of 58 patients, and published in 2014, like the Japanese paper, it has more recent data on a patients that have not been included in previous ones. Dr. Torgerson and Dr. Ohcs helped work on this one. I think the main takeaway from this study is that patients living in Central and South America are at greater risk of contracting certain opportunistic infections that are not common in the US and EU, and have not been identified in previous studies of Hyper IgM.
Hirbod-Mobarakeh A1, Aghamohammadi A, Rezaei N.
The immunoglobulin class switch recombination deficiency or hyper-IgM syndrome is characterized by normal or elevated serum IgM and low serum levels of other immunoglobulins. Since the first reported patient with hyper-IgM, more than 200 patients with this phenotype resulted from CD40 ligand deficiency have been reported. However, in addition to this common finding, they presented with different manifestations like opportunistic infections, autoimmunity and malignancies each of them are worth a detailed look. In this review, we will focus on different underlying mechanisms of these presentations to review what we have learned from our patients. In the end, we will discuss different treatment options available for these patients using this knowledge.
This is an interesting study out of Iran from 2014, but not from a major journal. No new information or data here, but a good summary of many of the already published data on Hyper IgM. They combined all the previous data to get more than 200 patients (but does not include any recent (5-10 years) data). We find this study helpful for a few reasons: First, it has a really great references section at the end that basically includes 151 relevant published study on Hyper IgM before 2014. Second, it has a good summary of many of the co-morbidities relating to Hyper IgM as well as good explanations on the diagnosis and prognosis of disease. Lastly, it has one of our favorite lines from any study regarding Hyper IgM Patients, one that guides our foundation’s approach: “Effective management of CD40L deficiency requires a comprehensive individualized look to each patient regarding his/her course of disease and various manifestations. In this view, each efficiently managed patient is an individual piece of art.”
Lee WI1, Torgerson TR, Schumacher MJ, Yel L, Zhu Q, Ochs HD.
The hyper immunoglobulin M (IgM) syndrome (HIGM), characterized by recurrent infections, low serum IgG and IgA, normal or elevated IgM, and defective class switch recombination and somatic hypermutation, is a heterogenous disorder with at least 5 distinct molecular defects, including mutations of the genes coding for the CD40 ligand (CD40L) and IKK-gamma (NEMO) genes, both X-linked; and mutations of CD40, activation-induced cytidine deaminase (AICDA), and uracil-DNA glycosylase (UNG), associated with autosomal recessive HIGM syndromes. To investigate the molecular basis of HIGM, we determined the prevalence of mutations affecting these 5 genes in a cohort of 140 patients (130 males and 10 females). Those patients without a molecular diagnosis were subsequently evaluated for mutations of the following genes: inducible CO-stimulator molecule (ICOS), ICOS ligand (ICOSL), and if male, Bruton tyrosine kinase (Btk) and SLAM-associated protein (SAP/SH2D1A). We found mutations of CD40L in 98 males; AICDA in 4 patients (3 males, 1 female); UNG in one adult male; and Btk in 3 boys. Of the remaining 25 males, one infant with hypohidrotic ectodermal dysplasia had a mutation of NEMO. None of the remaining 33 patients (24 males/9 females) had mutations affecting CD40, ICOS, ICOSL, or SH2D1, and are best classified as common variable immune deficiency (CVID), although other genes, including some not yet identified, may be responsible.
This study shows that the overall prevalence of CD40 Ligand Deficiency is approximately 70% of all Hyper IgM Syndrome cases.
Winkelstein JA1, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, Stiehm ER, Conley ME.
The X-linked hyper-IgM (XHIGM) syndrome is an uncommon primary immunodeficiency disease caused by mutations in the gene for CD40 ligand and characterized by normal or elevated serum IgM, reduced levels of IgG and IgA, and defective T-cell function. Because of its rarity, it has been difficult for any single investigator or institution to develop a comprehensive clinical picture of this disorder. Accordingly, a national registry was developed in the United States to provide demographic, genetic, immunologic, and clinical information on a relatively large number of patients with the XHIGM syndrome.A total of 79 patients from 60 unrelated families were registered between January 1997 and July 2002. The estimated minimal incidence was approximately 1/1,030,000 live births. All of the patients had significant IgG deficiency and most had IgA deficiency, but only one-half had elevated IgM levels. Most patients presented initially with a history of an increased susceptibility to infection including Pneumocystis carinii pneumonia. The average age of diagnosis was significantly earlier in patients born into a family with a previously affected individual. However, only one-third of the patients born into a family with a previously affected individual were diagnosed exclusively because of the presence of the positive family history before any clinical symptoms developed. Over half the patients developed symptoms of immunodeficiency and were diagnosed by 1 year of age, and over 90% by 4 years of age. The most prominent clinical infections were pneumonia (81% of patients), upper respiratory infections (49%) including sinusitis (43%) and recurrent otitis (43%), recurrent/protracted diarrhea (34%), central nervous system infections (14%), sepsis (13%), cellulitis (13%), hepatitis (9%), and osteomyelitis (1%). In addition to infections caused by encapsulated bacteria, opportunistic infections were relatively common and were caused by P. carinii, members of the herpes virus family (including cytomegalovirus), Cryptosporidium, Cryptococcus, Candida, Histoplasma, and Bartonella. Sclerosing cholangitis occurred in 5 patients and in 4 of these was associated with Cryptosporidium infection. Eight patients had died at the time of their entry into the Registry; 2 of pneumonia (1 P. carinii and 1 cytomegalovirus), 2 of encephalitis (1 ECHO virus and 1 cytomegalovirus), 2 of malignancy (both hepatocellular carcinoma), 1 of sclerosing cholangitis caused by Cryptosporidium, and 1 of hemolytic uremic syndrome.
This is the first large cohort paper on Hyper IgM Syndrome in the US, based on the original registry created for Hyper IgM Syndrome in 2002. These patients data would later be moved into the USIDNET registry. As with Levy et al, having a large cohort brings new insight to the overall clinical picture of the disorder as well as some insight into the prevalence. Lower rates of Cryptosporidium were observed then the European study, but it is not clear if this is a result of better water supply or a difference in how the patients were ascertained in European data. Another key take away is that despite 28 of the 79 patients being born into families with a previous affected member, only 9 were diagnosed before developing an infection (like PCP/PJP). This emphasizes the importance of attention to positive family history in order to diagnose and treat before symptoms develop.
Gennery AR1, Khawaja K, Veys P, Bredius RG, Notarangelo LD, Mazzolari E, Fischer A, Landais P, Cavazzana-Calvo M, Friedrich W, Fasth A, Wulffraat NM, Matthes-Martin S, Bensoussan D, Bordigoni P, Lange A, Pagliuca A, Andolina M, Cant AJ, Davies EG.
CD40 ligand (CD40L) deficiency causes recurrent sinopulmonary infection, Pneumocystis carinii pneumonia, and Cryptosporidium parvum infection. Approximately 40% to 50% of patients survive to the third decade: long-term survival is unclear. Hematopoietic stem cell transplantation (HSCT) is curative. We present a retrospective analysis of 38 European patients undergoing HSCT for CD40L deficiency in 8 European countries between 1993 and 2002. Donor stem cell source included 14 HLA-identical siblings, 22 unrelated donors, and 2 phenotypically matched parental stem cells (12 T-cell depleted). Of the patients, 34 engrafted and 26 (68%) survived; 3 had autologous reconstitution, 22 (58%) were cured, and 1 engrafted but has poor T-cell immune reconstitution. There were 18 evaluated patients who responded to vaccination. Of the patients, 12 (32%) died from infection-related complications, with severe cryptosporidiosis in 6. Grades 2 to 4 graft-versus-host disease (GvHD) associated with infection occurred in 6 of 12 fatal cases. HSCT cured 58% of patients, 72% of those without hepatic disease. Early T-cell function following whole marrow HSCT may limit cryptosporidial disease, but survival was similar after T-cell-depleted HSCT. Preexisting lung damage was the most important adverse risk factor. Further studies will determine optimal timing and type of HSCT
This is one of the more important studies that have been done on Hyper IgM, albeit, outdated (2004) and containing data from 1993-2002 from the European registries. This study includes 38 EU patients undergoing HSCT. Dr. Gennery is working on a follow up study that should cover the next 10 years or so and many more patients. As for outcomes, this older study shows similar life expectancy as some of the more recent ones. The HSCT outcomes have improved a lot since this data was collected. This is due to advances in HSCT, but also due to patients going into HSCT while still young and healthy as opposed to a last resort and when older.
Clinical spectrum of X-linked hyper-IgM syndrome (July 1997)
Jacov Levy, MD, Teresa Espanol-Boren, MD, Carolin Thomas, MD, Alain Fischer, MD, Pierangelo Tovo, MD, Pierre Bordigoni, MD, Igor Resnick, MD, Anders Fasth, MD, PhD, Maija Baer, MD, Lina Gomez, MD, E.A.M. Sanders, MD, Marie-Dominique Tabone, MD, Dominique Plantaz, MD, Amos Etzioni, MD, Virginia Monafo, MD, Mario Abinun, MD, Lennart Hammarstrom, MD, PhD, Tore Abrahamsen, MD, Allison Jones, MD, Adam Finn, MD, Timo Klemola, MD, Esther DeVries, MD, Ozden Sanal, MD, Manuel C. Peitsch, MD, Luigi D. Notarangelo, MD.
We report the clinical and immunologic features and outcome in 56 patients with X-linked hyper-IgM syndrome, a disorder caused by mutations in the CD40 ligand gene. Upper and lower respiratory tract infections (the latter frequently caused by Pneumocystis carinii), chronic diarrhea, and liver involvement (both often associated with Cryptosporidium infection) were common. Many patients had chronic neutropenia associated with oral and rectal ulcers. The marked prevalence of infections caused by intracellular pathogens suggests some degree of impairment of cell-mediated immunity. Although lymphocyte counts and in vitro proliferation to mitogens were normal, a defective in vitro proliferative response to antigens was observed in some patients, and additional defects of cell-mediated immunity may be presumed on the basis of current knowledge of CD40-ligand function. All patients received regular infusions of immunoglobulins. Four patients underwent liver transplantation because of sclerosing cholangitis, which relapsed in there. Three patients underwent bone marrow transplantation. Thirteen patients (23%) died of infection and/or liver disease. X-linked hyper-IgM syndrome, once considered a clinical variant of hypogammaglobulinemia, is a severe immunodeficiency with significant cellular involvement and a high mortality rate.
This is one of the first major studies and one of the most referenced for Hyper IgM. Conducted by Dr. Notarangelo and Dr. Levy it included 56 patient data collected from around Europe up until 1996. This study has only 3 patients who had HSCT as this is just starting to be an option to XHIM. This study only showed a 20% 25 year survival rate.
Please stay tuned for updated relevant content on this page. The Hyper IgM Foundation is in its early stages, but we are working hard to bring you the most accurate and comprehensive information about this very rare immune deficiency.
Please help us fulfill our mission to improve the treatment, quality of life and the long term outlook for children and adults living with Hyper IgM through research, support, education, and advocacy to families and patients by getting involved in these ways:
We are looking for enthusiastic volunteers around the world that can donate their time and passion to the Hyper IgM Foundation. There are many ways to get involved, from helping create content and compile data for our website, to serving as a parent-to-parent mentor for newly diagnosed families. We are also looking for volunteers with experience with website design, art design, accounting, and more. Please email email@example.com with subject line “Volunteer,” your name, contact information and a short description and we will be in touch.
We are looking for experienced writers to help write and edit content for our website. Medical writing experience is a major plus, as we hope to provide updated relevant information about Hyper IgM Syndrome and immune deficiencies on an ongoing basis. Please email firstname.lastname@example.org with subject line “Write,” your name, contact information and a short description and we will be in touch.
We are looking for patient stories to be featured on the Hyper IgM Foundation blog as well as patients’ blogs to be featured on our Community Blog section. If you are interested in having your story shared with other Hyper IgM families and physicians so they can learn from your experiences please email email@example.com with subject line “Blogger,” your name, contact information and a short description and we will be in touch.
The key to our success is to grow our fanbase and following. Please take the time to connect with us on social media and share the Hyper IgM Foundation’s story with your friends and family.
Support the Hyper IgM Foundation and/or share our donation page with your friends and family to help us fulfill our mission. Funds raised will go to improve the treatment, quality of life and the long term outlook for children and adults living with Hyper IgM through research, support, education, and advocacy to families and patients.